{"filing":{"accession_number":"0001193125-26-277513","cik":"0001869105","ticker":"BBOT","company_name":"BridgeBio Oncology Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"d137002d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1869105/000119312526277513/d137002d8k.htm"},"events":[{"id":12737,"run_id":11301,"accession_number":"0001193125-26-277513","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"BridgeBio held its Annual Meeting of Stockholders on June 16, 2026, at which shareholders voted on the election of two Class I directors (Peter Lebowitz and Frank P. McCormick) and the ratification of Deloitte \u0026 Touche LLP as independent auditor, with detailed vote tallies disclosed.","company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9673,"accession_number":"0001193125-26-277513","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of an Annual Meeting of Stockholders held on June 16, 2026. The filing presents voting results for two proposals: (1) election of two Class I directors (Peter Lebowitz and Frank P. McCormick) with specified vote counts for and against, and (2) ratification of Deloitte \u0026 Touche LLP as the independent auditor. The disclosure includes share counts, quorum information, and detailed vote tallies, which are the hallmarks of shareholder vote results required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:48:24.426562+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12738,"run_id":11301,"accession_number":"0001193125-26-277513","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":false,"confidence":0.85,"summary":"Michelle Doig resigned as a member of the Board of Directors effective June 16, 2026, upon completion of her Class I director term, in a routine and non-controversial transition.","company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9672,"accession_number":"0001193125-26-277513","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"Michelle Doig resigned as a member of the Board of Directors effective June 16, 2026, upon completion of her Class I director term. While this is a departure event, it is routine and non-controversial—explicitly stated as not due to any disagreement and occurring as a normal term completion at the Annual Meeting. This is a standard board transition rather than a material event affecting investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:48:24.426562+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9672,"accession_number":"0001193125-26-277513","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":false,"confidence":0.85,"reasoning":"Michelle Doig resigned as a member of the Board of Directors effective June 16, 2026, upon completion of her Class I director term. While this is a departure event, it is routine and non-controversial—explicitly stated as not due to any disagreement and occurring as a normal term completion at the Annual Meeting. This is a standard board transition rather than a material event affecting investor assessment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:48:24.426562+00:00","company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","filing_date":"2026-06-22"},{"id":9673,"accession_number":"0001193125-26-277513","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of an Annual Meeting of Stockholders held on June 16, 2026. The filing presents voting results for two proposals: (1) election of two Class I directors (Peter Lebowitz and Frank P. McCormick) with specified vote counts for and against, and (2) ratification of Deloitte \u0026 Touche LLP as the independent auditor. The disclosure includes share counts, quorum information, and detailed vote tallies, which are the hallmarks of shareholder vote results required under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:48:24.426562+00:00","company_name":"BridgeBio Oncology Therapeutics, Inc.","ticker":"BBOT","filing_date":"2026-06-22"}]}